Advanced search    

Search: authors:"Paul O’Byrne"

4 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Therapeutic interventions in severe asthma

The present paper addresses severe asthma which is limited to 5-10% of the overall population of asthmatics. However, it accounts for 50% or more of socials costs of the disease, as it is responsible for hospitalizations and Emergency Department accesses as well as expensive treatments. The recent identification of different endotypes of asthma, based on the inflammatory pattern, ...

Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma

Background Fluticasone furoate is a once-daily inhaled corticosteroid. This report provides an overview of safety and efficacy data that support the use of once-daily fluticasone furoate 100 μg or 200 μg in adult and adolescent asthma patients. Methods Fourteen clinical studies (six Phase II and eight Phase III) were conducted as part of the fluticasone furoate global clinical ...

The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given ‘as needed’ in mild asthma: study protocols for two randomised controlled trials

Background In many patients with mild asthma, the low frequency of symptoms and the episodic nature of exacerbations make adherence to regular maintenance treatment difficult. This often leads to over-reliance on short-acting β 2 -agonist (SABA) reliever medication and under-treatment of the underlying inflammation, with poor control of asthma symptoms and increased risk of ...

Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β 2 -agonist, in patients with asthma: results of a parallel-group study and a crossover study

Background Olodaterol is a novel, inhaled long-acting β 2 -agonist (LABA) with >24-hour duration of action investigated in asthma and chronic obstructive pulmonary disease. Methods Two multicentre studies examined the efficacy and safety of 4 weeks’ once-daily (QD) olodaterol (2, 5, 10 and 20 μg, with background inhaled corticosteroids) in patients with asthma. One randomised, ...